These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1236 related articles for article (PubMed ID: 11245477)
41. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684 [TBL] [Abstract][Full Text] [Related]
42. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Wada N; Maeda H; Yoshimine Y; Akamine A Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598 [TBL] [Abstract][Full Text] [Related]
43. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts. Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722 [TBL] [Abstract][Full Text] [Related]
44. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice. Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189 [TBL] [Abstract][Full Text] [Related]
45. In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells. Granchi D; Amato I; Battistelli L; Avnet S; Capaccioli S; Papucci L; Donnini M; Pellacani A; Brandi ML; Giunti A; Baldini N Int J Cancer; 2004 Oct; 111(6):829-38. PubMed ID: 15300794 [TBL] [Abstract][Full Text] [Related]
46. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1. Sankar U; Patel K; Rosol TJ; Ostrowski MC J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022 [TBL] [Abstract][Full Text] [Related]
47. Regulation of osteoclastogenesis by gap junction communication. Matemba SF; Lie A; Ransjö M J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710 [TBL] [Abstract][Full Text] [Related]
48. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. Tsurukai T; Udagawa N; Matsuzaki K; Takahashi N; Suda T J Bone Miner Metab; 2000; 18(4):177-84. PubMed ID: 10874596 [TBL] [Abstract][Full Text] [Related]
49. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. Kondo H; Guo J; Bringhurst FR J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438 [TBL] [Abstract][Full Text] [Related]
50. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. Shiotani A; Takami M; Itoh K; Shibasaki Y; Sasaki T Anat Rec; 2002 Oct; 268(2):137-46. PubMed ID: 12221720 [TBL] [Abstract][Full Text] [Related]
51. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. Lee SK; Lorenzo JA Bone; 2002 Jul; 31(1):252-9. PubMed ID: 12110442 [TBL] [Abstract][Full Text] [Related]
52. Dual modulation of osteoclast differentiation by lipopolysaccharide. Zou W; Bar-Shavit Z J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834 [TBL] [Abstract][Full Text] [Related]
53. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Atkins GJ; Bouralexis S; Haynes DR; Graves SE; Geary SM; Evdokiou A; Zannettino AC; Hay S; Findlay DM Bone; 2001 Apr; 28(4):370-7. PubMed ID: 11336917 [TBL] [Abstract][Full Text] [Related]
54. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456 [TBL] [Abstract][Full Text] [Related]
55. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. Khapli SM; Mangashetti LS; Yogesha SD; Wani MR J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992 [TBL] [Abstract][Full Text] [Related]
56. Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. Hasegawa T; Yoshimura Y; Kikuiri T; Yawaka Y; Takeyama S; Matsumoto A; Oguchi H; Shirakawa T J Periodontal Res; 2002 Dec; 37(6):405-11. PubMed ID: 12472833 [TBL] [Abstract][Full Text] [Related]
57. Breast cancer cells interact with osteoblasts to support osteoclast formation. Thomas RJ; Guise TA; Yin JJ; Elliott J; Horwood NJ; Martin TJ; Gillespie MT Endocrinology; 1999 Oct; 140(10):4451-8. PubMed ID: 10499498 [TBL] [Abstract][Full Text] [Related]
58. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro. Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896 [TBL] [Abstract][Full Text] [Related]
59. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985 [TBL] [Abstract][Full Text] [Related]
60. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. Yu X; Huang Y; Collin-Osdoby P; Osdoby P J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]